Bruker Corporation (BRKR)

From the record

Bruker Corporation's filings since 2017 show 3 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2020-03-05); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2020-03-03) (its current reports).

From the record

Bruker Corporation's 9 filed years say what it did: revenue went from $1.8 billion in fiscal 2017 to $3.4 billion in fiscal 2025, up 8.7% a year; it rose in 7 of 8 years; the deepest fall was 4% from fiscal 2019 to fiscal 2020; net income was positive in 8 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Bruker Corporation's diluted share count grew about 0.5% a year, and dividends and buybacks returned about 33% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 16 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Bruker Corporation lost about 0 cents for every dollar of shareholders' money, and gross profitability: its products earned about 25 cents per dollar of everything the company owns. Leverage: it owed about 60 cents per dollar of assets, and net share issuance: its share count grew 1.5% over the year (the filed statements).

From the record

Bruker Corporation's standing among 21 graded names in its industry family: revenue of $3.4 billion in fiscal 2025 ranks in the top 21% by size; a net margin of -0.2% ranks in the top 31%; revenue growth of 10.7% a year over the last 3 filed years ranks in the top 12% (its annual reports).

From the record

Bruker Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Laukien, Frank H (PRESIDENT & CEO, as filed), filing under that title since 2006-01-09, 20.8 years (top 3% of its family); the 19 officers and directors filing in the last fifteen months have been on the record a median of 10.5 years (top 2%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 19 people in charge now (top 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Bruker Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $299 million against debt of $1.9 billion leaves -25.2% of its assets as net cash, bottom 16% of its family; cash from operations less capital spending is 1.3% of revenue (top 50%); a gross margin of 45.9% (bottom 25%); research spending of 11.5% of revenue (bottom 38%) (its annual report).

From the record

Bruker Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 10.7% a year over the last three filed years against 8.7% over all 9, speeding up (top 12% of its family); the newest year grew 2.1% (top 50%); research spending grew 18.8% a year (top 12%); capital spending grew -11.1% a year (top 47%) (its annual reports). Bruker Corporation reported 4 lines of business in fiscal 2025: Bsi Calid at $1.2 billion (35%), Bsi Nano at $1.1 billion (32%), Bsi Biospin at $879 million (26%), and 1 more; 1 of 4 grew against the year before (its annual report).

From the record

Bruker Corporation's newest year against its own record: revenue of $3.4 billion in fiscal 2025 came in 11.5% below the $3.9 billion its prior three years' pace pointed to (bottom 18% of its family); net income of $8 million against a prior three-year average of $280 million (bottom 23%); a net margin of -0.2% against 9.9% before (bottom 38%) (its annual reports).